{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:40:38Z","timestamp":1777102838453,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clinthera.2023.06.022","type":"journal-article","created":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T07:49:37Z","timestamp":1693036177000},"page":"868-872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bleeding Complications in Vancomycin-Induced Thrombocytopenia: A Real-world Postmarketing Pharmacovigilance Analysis"],"prefix":"10.1016","volume":"45","author":[{"given":"Hui","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoling","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.06.022_bib0001","article-title":"Life-threatening intrapulmonary hemorrhage due to vancomycin-induced thrombocytopenia: a case report","volume":"2020","author":"Abdalhadi","year":"2020","journal-title":"Case Rep Crit Care"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0002","article-title":"Severe thrombocytopenia caused by vancomycin in the intensive care unit: a case report","volume":"9","author":"Li","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0003","first-page":"e23328","article-title":"A rare case of vancomycin-induced immune thrombocytopenia","volume":"14","author":"Hameed","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01453-17","article-title":"Thrombocytopenia with tedizolid and linezolid","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0005","first-page":"1649","article-title":"Linezolid vs vancomycin in induced thrombocytopenia","volume":"11","author":"Al-Harbi","year":"2022","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12959-022-00369-z","article-title":"Coagulation dysfunction events associated with tigecycline: a real-world study from FDA Adverse Event Reporting System (FAERS) database","volume":"20","author":"Guo","year":"2022","journal-title":"Thromb J"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0007","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/sdi.13024","article-title":"Intraperitoneal vancomycin-induced immune thrombocytopenia","volume":"35","author":"Murt","year":"2022","journal-title":"Semin Dial"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-224682","article-title":"Documented vancomycin-induced severe immune-mediated thrombocytopaenia","volume":"2018","author":"Gerstein","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0009","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.2169\/internalmedicine.55.6902","article-title":"Vancomycin-induced immune thrombocytopenia proven by the detection of vancomycin-dependent anti-platelet antibody with flow cytometry","volume":"55","author":"Yamanouchi","year":"2016","journal-title":"Intern Med"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-208192","article-title":"Life-threatening haematuria caused by vancomycin-induced thrombocytopenia","volume":"2015","author":"Lobo","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0011","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(85)91710-6","article-title":"Thrombocytopenia due to vancomycin","volume":"1","author":"Walker","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0012","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood.V84.1.176.176","article-title":"Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb\/IIIa complex","volume":"84","author":"Curtis","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100951","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: a safety analysis of clinical trials and FDA pharmacovigilance database","volume":"37","author":"Zhu","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0014","first-page":"405","article-title":"Evaluation of signal of detection for platinum compounds in Canadian spontaneous adverse event reports","author":"Singhal","year":"2015","journal-title":"Int J Pharm Pharmaceut Sci"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0015","doi-asserted-by":"crossref","unstructured":"Sharwan S, Chakraborty BS. Signal detection for cyclophosphamide: Canadian Adverse Reaction Monitoring Program (CADRMP). 2015;2015:341\u2013348.","DOI":"10.5530\/jyp.2015.4.8"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0016","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa065066","article-title":"Vancomycin-induced immune thrombocytopenia","volume":"35","author":"Von Drygalski","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-243027","article-title":"Rapid onset vancomycin-induced thrombocytopenia confirmed by vancomycin antibody test","volume":"14","author":"Rattanasuwan","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0018","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.12998\/wjcc.v9.i7.1696","article-title":"Vancomycin-induced thrombocytopenia in endocarditis: a case report and review of literature","volume":"9","author":"Guleng","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0019","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/jth.12852","article-title":"Platelet Immunology Scientific Subcommittee of the International Society of Thrombosis on Hemostasis. Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH","volume":"13","author":"Arnold","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0020","first-page":"e7940","article-title":"A case of vancomycin-induced immune thrombocytopenia","volume":"12","author":"MacDougall","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0021","doi-asserted-by":"crossref","first-page":"e01398","DOI":"10.1016\/j.idcr.2022.e01398","article-title":"Re-exposure causing rapid onset of vancomycin induced thrombocytopenia","volume":"27","author":"Boodhai","year":"2022","journal-title":"IDCases"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0022","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/1060028019867433","article-title":"Rapid-onset vancomycin-induced thrombocytopenia with reexposure","volume":"53","author":"Getz","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40264-016-0469-y","article-title":"Vancomycin-induced thrombocytopenia: a narrative review","volume":"40","author":"Mohammadi","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1159\/000503418","article-title":"Vancomycin induced thrombocytopenia - protracted course in a hemodialysis patient","volume":"12","author":"Ajit","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0025","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.3390\/jcm9072212","article-title":"Pathophysiology and diagnosis of drug-induced immune thrombocytopenia","volume":"9","author":"Vayne","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0026","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood-2015-04-643148","article-title":"Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb\/IIIa","volume":"126","author":"Bougie","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0027","article-title":"Structural basis for quinine-dependent antibody binding to platelet integrin alphaIIbbeta3","volume":"126","author":"Zhu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101345","article-title":"Reported pericardial toxicities associated with acute myelogenous leukemia treatments: a pharmacovigilance analysis of the FDA Adverse Reporting Database","volume":"47","author":"Janus","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.clinthera.2023.06.022_bib0029","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:22Z","timestamp":1758963622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823002291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0149291823002291"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.06.022","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding Complications in Vancomycin-Induced Thrombocytopenia: A Real-world Postmarketing Pharmacovigilance Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}